What is PATH EX?
PATH EX is a specialized medical technology firm dedicated to the development of advanced extracorporeal blood cleansing devices. The company's core innovation lies in its ability to selectively remove pathogens and endotoxins directly from a patient's bloodstream. This targeted approach is specifically engineered to combat sepsis, a life-threatening condition that requires immediate and precise clinical intervention. By focusing on the mechanical removal of infectious agents, PATH EX provides a unique therapeutic alternative to traditional pharmacological treatments, which may be limited by antibiotic resistance or delayed efficacy. The company's technology is currently positioned to serve critical care units and infectious disease departments, where the speed and accuracy of blood purification can significantly influence patient outcomes.
How much funding has PATH EX raised?
PATH EX has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2025): $5M with participation from IAG Capital Partners, Fitz Gate Ventures, and TMC Ventures
Key Investors in PATH EX
IAG Capital Partners
IAG Capital Partners is a venture capital firm that specializes in leading investment rounds from seed to Series C, providing financial support to innovative companies at various stages of their development.
Fitz Gate Ventures
Fitz Gate Ventures is an early stage venture capital firm that focuses on deeptech startups, leveraging a proprietary community network to provide strategic advantages to its portfolio companies.
TMC Ventures
TMC Ventures specializes in providing evidence-based health solutions and strategic support, focusing on validated technologies that address critical health concerns.
What's next for PATH EX?
Looking ahead, the strategic deployment of this capital will likely focus on scaling manufacturing capabilities and advancing regulatory pathways for its flagship blood cleansing platforms. As the company moves toward larger clinical trials, the focus will remain on demonstrating the efficacy of its technology in reducing bacterial concentrations in real-world critical care environments. The backing from institutional investors suggests a long-term commitment to navigating the complex regulatory landscape of medical devices. Future growth will be defined by the company's ability to integrate its solutions into existing hospital workflows, thereby establishing a robust footprint in the global infectious disease market and providing clinicians with a powerful tool to mitigate the mortality risks associated with severe bacteremia.
See full PATH EX company page
